These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2526330)

  • 1. Biodistribution and scintigraphy of 11C-toremifene in rats bearing DMBA-induced mammary carcinoma.
    Kangas L; Haaparanta M; Paul R; Roeda D; Sipilä H
    Pharmacol Toxicol; 1989 Apr; 64(4):373-7. PubMed ID: 2526330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative double-tracer whole-body autoradiography: uptake of 11C-, 18F- and 3H-labeled compounds in rat tumors.
    d'Argy R; Paul R; Frankenberg L; Stålnacke CG; Lundqvist H; Kangas L; Halldin C; Någren K; Roeda D; Haaparanta M
    Int J Rad Appl Instrum B; 1988; 15(5):577-85. PubMed ID: 2978293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat.
    di Salle E; Zaccheo T; Ornati G
    J Steroid Biochem; 1990 Jun; 36(3):203-6. PubMed ID: 2142233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model.
    Robinson SP; Mauel DA; Jordan VC
    Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1817-21. PubMed ID: 2975594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the c-Ha-ras and neu oncogenes in DMBA-induced, anti-estrogen-treated rat mammary tumors.
    Vuorio T; Wärri A; Sandberg M; Alitalo K; Vuorio E
    Int J Cancer; 1988 Nov; 42(5):774-9. PubMed ID: 2972630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
    Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
    Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and pharmacological effects of toremifene metabolites.
    Kangas L
    Cancer Chemother Pharmacol; 1990; 27(1):8-12. PubMed ID: 2147128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution of 123I-labeled 4-hydroxytamoxifen derivatives in rats with dimethylbenzanthracene-induced mammary carcinomas.
    Kruijer PS; Klok RP; van den Koedijk CD; Blankenstein MA; Voskuil JH; Verzeijlbergen JF; Ensing GJ; Herscheid JD
    Nucl Med Biol; 1997 Nov; 24(8):719-22. PubMed ID: 9428596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of combination toremifene and medroxyprogesterone acetate (MPA) in vitro and in vivo.
    Kangas L; Grönroos M
    J Steroid Biochem; 1990 Jun; 36(3):253-7. PubMed ID: 2142248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive and synergistic antitumor effects with toremifene and interferons.
    Kangas L; Cantell K; Schellekens H
    J Steroid Biochem; 1990 Jun; 36(3):259-62. PubMed ID: 2142249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The measurement of tamoxifen and metabolites in the rat and relationship to the response of DMBA-induced mammary tumours.
    Daniel CP; Gaskell SJ; Nicholson RI
    Eur J Cancer Clin Oncol; 1984 Jan; 20(1):137-43. PubMed ID: 6420159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
    Kawamura I; Mizota T; Kondo N; Shimomura K; Kohsaka M
    Jpn J Pharmacol; 1991 Oct; 57(2):215-24. PubMed ID: 1812300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen as an anti-tumour agent: effect on oestrogen binding.
    Jordan VC; Dowse LJ
    J Endocrinol; 1976 Feb; 68(02):297-303. PubMed ID: 176295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-oestrogen action in experimental breast cancer.
    Jordan VC; Naylor KE; Dix CJ; Prestwich G
    Recent Results Cancer Res; 1980; 71():30-44. PubMed ID: 6768113
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluating the response to antioestrogen toremifene treatment in DMBA induced rat mammary carcinoma.
    Huovinen R; Kellokumpu-Lehtinen PL; Collan Y
    Int J Exp Pathol; 1994 Aug; 75(4):257-63. PubMed ID: 7947228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the pharmacological properties of toremifene.
    Kangas L
    J Steroid Biochem; 1990 Jun; 36(3):191-5. PubMed ID: 2142231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma.
    Toko T; Shibata J; Sugimoto Y; Yamaya H; Yoshida M; Ogawa K; Matsushima E
    Cancer Chemother Pharmacol; 1995; 37(1-2):7-13. PubMed ID: 7497599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo binding of toremifene and its metabolites in rat uterus.
    Simberg NH; Murai JT; Siiteri PK
    J Steroid Biochem; 1990 Jun; 36(3):197-202. PubMed ID: 2142232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitotic activity, apoptosis and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with anti-estrogen toremifene.
    Huovinen R; Wärri A; Collan Y
    Int J Cancer; 1993 Oct; 55(4):685-91. PubMed ID: 8407000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The significance of estrogen receptors in tamoxifen and toremifene therapy.
    Valavaara R; Kangas L
    Ann Clin Res; 1988; 20(5):380-8. PubMed ID: 2975479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.